Higher levels of interleukin IL-17 and antigen-specific IL-17 responses in pulmonary sarcoidosis patients with Löfgren's syndrome

Clinical and Experimental Immunology

Volumn 178, Issue 2, 2014, Pages 342-352

  Ostadkarampour, M ^a   Eklund, A ^a   Moller, D ^c   Glader, P ^b   Olgart Hoglund C ^a   Linden A ^a   Grunewald, J ^a   Wahlstrom J ^a  

^a KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^b UNIVERSITY OF GOTHENBURG   (Sweden)

^c JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Cytokines; IL 17; Inflammation; Sarcoidosis; T cells

Indexed keywords

BACTERIAL PROTEIN; CATALASE; HLA DR3 ANTIGEN; INTERLEUKIN 17; KATG PROTEIN, MYCOBACTERIUM TUBERCULOSIS; T LYMPHOCYTE RECEPTOR;

ADULT; BRONCHOALVEOLAR LAVAGE FLUID; FEMALE; GENE EXPRESSION; GENETICS; HUMAN; IMMUNOLOGY; LYMPHOCYTE ACTIVATION; MALE; METABOLISM; MIDDLE AGED; RISK FACTOR; SARCOIDOSIS, PULMONARY; T LYMPHOCYTE SUBPOPULATION; TH17 CELL;

ADULT; BACTERIAL PROTEINS; BRONCHOALVEOLAR LAVAGE FLUID; CATALASE; FEMALE; GENE EXPRESSION; HLA-DR3 ANTIGEN; HUMANS; INTERLEUKIN-17; LYMPHOCYTE ACTIVATION; MALE; MIDDLE AGED; RISK FACTORS; SARCOIDOSIS, PULMONARY; T-CELL ANTIGEN RECEPTOR SPECIFICITY; T-LYMPHOCYTE SUBSETS; TH17 CELLS;

EID: 84908151919     PISSN: 00099104     EISSN: 13652249     Source Type: Journal    
DOI: 10.1111/cei.12403     Document Type: Article

References (35)

1. Valeyre D, Prasse A, Nunes H, Uzunhan Y, Brillet PY, Muller-Quernheim J. Sarcoidosis. Lancet 2013; S0140-6736:60680-60687.
2. Chen ES, Moller DR. Sarcoidosis-scientific progress and clinical challenges. Nat Rev Rheumatol 2011; 7:457-467.
3. Iannuzzi MC, Rybicki BA, Teirstein AS. Sarcoidosis. N Engl J Med 2007; 357:2153-2165.
4. Grunewald J, Eklund A. Lofgren's syndrome: human leukocyte antigen strongly influences the disease course. Am J Respir Crit Care Med 2009; 179:307-312.
5. Grunewald J, Janson CH, Eklund A etal. Restricted V alpha 2.3 gene usage by CD4+ T lymphocytes in bronchoalveolar lavage fluid from sarcoidosis patients correlates with HLA-DR3. Eur J Immunol 1992; 22:129-135.
6. Saboor SA, Johnson NM, McFadden J. Detection of mycobacterial DNA in sarcoidosis and tuberculosis with polymerase chain reaction. Lancet 1992; 339:1012-1015.
7. Song Z, Marzilli L, Greenlee BM etal. Mycobacterial catalase-peroxidase is a tissue antigen and target of the adaptive immune response in systemic sarcoidosis. J Exp Med 2005; 201:755-767.
8. Chen ES, Wahlstrom J, Song Z etal. T cell responses to mycobacterial catalase-peroxidase profile a pathogenic antigen in systemic sarcoidosis. J Immunol 2008; 181:8784-8796.
9. Wynn TA. T(H)-17: a giant step from T(H)1 and T(H)2. Nat Immunol 2005; 6:1069-1070.
10. Glader P, Smith ME, Malmhall C etal. Interleukin-17-producing T-helper cells and related cytokines in human airways exposed to endotoxin. Eur Respir J 2010; 36:1155-1164.
11. Kolls JK. CD4(+) T-cell subsets and host defense in the lung. Immunol Rev 2013; 252:156-163.
12. Okamoto Yoshida Y, Umemura M, Yahagi A etal. Essential role of IL-17A in the formation of a mycobacterial infection-induced granuloma in the lung. J Immunol 2010; 184:4414-4422.
13. Vanaudenaerde BM, Verleden SE, Vos R etal. Innate and adaptive interleukin-17-producing lymphocytes in chronic inflammatory lung disorders. Am J Respir Crit Care Med 2011; 183:977-986.
14. Ten Berge B, Paats MS, Bergen IM etal. Increased IL-17A expression in granulomas and in circulating memory T cells in sarcoidosis. Rheumatology (Oxf) 2012; 51:37-46.
15. Facco M, Cabrelle A, Teramo A etal. Sarcoidosis is a Th1/Th17 multisystem disorder. Thorax 2010; 66:144-150.
16. Statement on sarcoidosis. Joint Statement of the American Thoracic Society (ATS), the European Respiratory Society (ERS) and the World Association of Sarcoidosis and Other Granulomatous Disorders (WASOG) adopted by the ATS Board of Directors and by the ERS Executive Committee, February 1999. Am J Respir Crit Care Med 1999; 160:736-755.
17. Grunewald J, Wahlstrom J, Berlin M, Wigzell H, Eklund A, Olerup O. Lung restricted T cell receptor AV2S3+ CD4+ T cell expansions in sarcoidosis patients with a shared HLA-DRbeta chain conformation. Thorax 2002; 57:348-352.
18. Wahlstrom J, Dengjel J, Winqvist O etal. Autoimmune T cell responses to antigenic peptides presented by bronchoalveolar lavage cell HLA-DR molecules in sarcoidosis. Clin Immunol 2009; 133:353-363.
19. Wiken M, Ostadkarampour M, Eklund A etal. Antigen-specific multifunctional T-cells in sarcoidosis patients with Lofgren's syndrome. Eur Respir J 2012; 40:110-121.
20. Richmond BW, Ploetze K, Isom J etal. Sarcoidosis Th17 cells are ESAT-6 antigen specific but demonstrate reduced IFN-gamma expression. J Clin Immunol 2013; 33:446-455.
21. Kolaczkowska E, Kubes P. Neutrophil recruitment and function in health and inflammation. Nat Rev Immunol 2013; 13:159-175.
22. Khader SA, Bell GK, Pearl JE etal. IL-23 and IL-17 in the establishment of protective pulmonary CD4+ T cell responses after vaccination and during Mycobacterium tuberculosis challenge. Nat Immunol 2007; 8:369-377.
23. Umemura M, Yahagi A, Hamada S etal. IL-17-mediated regulation of innate and acquired immune response against pulmonary Mycobacterium bovis bacille Calmette-Guérin infection. J Immunol 2007; 178:3786-3796.
24. Wilke CM, Bishop K, Fox D, Zou W. Deciphering the role of Th17 cells in human disease. Trends Immunol 2011; 32:603-611.
25. Hirota K, Ahlfors H, Duarte JH, Stockinger B. Regulation and function of innate and adaptive interleukin-17-producing cells. EMBO Rep 2012; 13:113-120.
26. Sergejeva S, Ivanov S, Lotvall J, Linden A. Interleukin-17 as a recruitment and survival factor for airway macrophages in allergic airway inflammation. Am J Respir Cell Mol Biol 2005; 33:248-253.
27. Ke Y, Liu K, Huang GQ etal. Anti-inflammatory role of IL-17 in experimental autoimmune uveitis. J Immunol 2009; 182:3183-3190.
28. O'Connor W, Jr, Kamanaka M, Booth CJ etal. A protective function for interleukin 17A in T cell-mediated intestinal inflammation. Nat Immunol 2009; 10:603-609.
29. Silverpil E, Glader P, Hansson M, Linden A. Impact of interleukin-17 on macrophage phagocytosis of apoptotic neutrophils and particles. Inflammation 2011; 34:1-9.
30. Lee Y, Awasthi A, Yosef N etal. Induction and molecular signature of pathogenic TH17 cells. Nat Immunol 2012; 13:991-999.
31. Idali F, Wiken M, Wahlstrom J etal. Reduced Th1 response in the lungs of HLA-DRB1*0301 patients with pulmonary sarcoidosis. Eur Respir J 2006; 27:451-459.
32. Monteleone I, Sarra M, Pallone F, Monteleone G. Th17-related cytokines in inflammatory bowel diseases: friends or foes? Curr Mol Med 2012; 12:592-597.
33. Ghoreschi K, Laurence A, Yang XP etal. Generation of pathogenic T(H)17 cells in the absence of TGF-beta signalling. Nature 2010; 467:967-971.
34. Genovese MC, Van den Bosch F, Roberson SA etal. LY2439821, a humanized anti-interleukin-17 monoclonal antibody, in the treatment of patients with rheumatoid arthritis: a phase I randomized, double-blind, placebo-controlled, proof-of-concept study. Arthritis Rheum 2010; 62:929-939.
35. Waisman A. To be 17 again-anti-interleukin-17 treatment for psoriasis. N Engl J Med 2012; 366:1251-1252.